ATE525394T1 - Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung - Google Patents

Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung

Info

Publication number
ATE525394T1
ATE525394T1 AT08758607T AT08758607T ATE525394T1 AT E525394 T1 ATE525394 T1 AT E525394T1 AT 08758607 T AT08758607 T AT 08758607T AT 08758607 T AT08758607 T AT 08758607T AT E525394 T1 ATE525394 T1 AT E525394T1
Authority
AT
Austria
Prior art keywords
vip
treatment
vasoactive intestinal
intestinal peptide
peptides
Prior art date
Application number
AT08758607T
Other languages
English (en)
Inventor
Michael Roth-Chiarello
Original Assignee
Res Internat Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Internat Sarl filed Critical Res Internat Sarl
Application granted granted Critical
Publication of ATE525394T1 publication Critical patent/ATE525394T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT08758607T 2007-05-21 2008-05-19 Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung ATE525394T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07010033 2007-05-21
PCT/EP2008/003989 WO2008141786A2 (en) 2007-05-21 2008-05-19 Peptides having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases

Publications (1)

Publication Number Publication Date
ATE525394T1 true ATE525394T1 (de) 2011-10-15

Family

ID=39828222

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08758607T ATE525394T1 (de) 2007-05-21 2008-05-19 Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung

Country Status (6)

Country Link
US (1) US8329640B2 (de)
EP (1) EP2152741B1 (de)
AT (1) ATE525394T1 (de)
CA (1) CA2687602C (de)
ES (1) ES2373824T3 (de)
WO (1) WO2008141786A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
PT2464370T (pt) 2009-08-14 2017-05-17 Phasebio Pharmaceuticals Inc Péptidos vasoativos intestinais modificados
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US9745384B2 (en) 2012-12-20 2017-08-29 The Brigham And Women's Hospital, Inc. Peptides useful for modulating histone demethylase function
AU2014216517B2 (en) * 2013-02-15 2017-04-06 Thomas Jefferson University Method for detecting shed or circulating tumor cells in biological fluids
AU2015255752B2 (en) * 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
CA2976038A1 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
EP3583933A1 (de) 2018-06-20 2019-12-25 Albert-Ludwigs-Universität Freiburg Verabreichung von aviptadil durch inhalation zur behandlung von chronischer berylliumkrankheit
KR20220005495A (ko) * 2019-05-07 2022-01-13 에드비타 라이프사이언스 게엠베하 약물-유도 간질성 폐렴의 치료에 사용하기 위한 혈관활성 장 펩티드(vip)
WO2022224172A1 (en) * 2021-04-20 2022-10-27 Advita Lifescience Ag Use of aviptadil alone or in combination with alpha lipoic acid as a therapeutic medicament for post-viral infection syndrome

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101229363A (zh) 2000-11-28 2008-07-30 蒙多生物技术许可股份公司 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物

Also Published As

Publication number Publication date
ES2373824T3 (es) 2012-02-09
US20100256044A1 (en) 2010-10-07
US8329640B2 (en) 2012-12-11
EP2152741B1 (de) 2011-09-21
CA2687602C (en) 2014-07-15
EP2152741A2 (de) 2010-02-17
WO2008141786A2 (en) 2008-11-27
WO2008141786A3 (en) 2009-02-05
CA2687602A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
ATE525394T1 (de) Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung
MX2007012700A (es) Compuestos organicos.
ATE430569T1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
AR066848A1 (es) Polipeptidos, dominios variables de anticuerpos y antagonistas del receptor de tipo 1 del factor de necrosis tumoral (tnfr1)
BRPI0819932A2 (pt) composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável.
JP2017000143A5 (de)
DE602005017636D1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
ATE516285T1 (de) Dihydropyridinonderivate
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
JP2008514618A5 (de)
UY27965A1 (es) Derivados heterocíclicos
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
EA201100942A1 (ru) Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
CY1115316T1 (el) Πεπτιδια για τη θεραπευτικη αγωγη βητα-αμυλοειδωσεων
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
DE602008005155D1 (de) Glp-1-fc fusionsprotein-formulierung
WO2008149144A3 (en) Polypeptides, antibody variable domains and antagonists
RU2016103067A (ru) Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей
NO20073900L (no) Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
ECSP22016558A (es) Proteínas de fusión terapéuticas
CL2009000250A1 (es) Compuestos derivados de pirazolo[3,4-b]piridina carboxamida; composicion farmaceutica que los comprende; y su uso en el tratamiento del asma, epoc y rinitis.
ECSP099029A (es) Nuevos análogos del péptido intestinal vasoactivo
EA201000161A1 (ru) Синтетические поверхностно-активные пептиды легких

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2152741

Country of ref document: EP